EP Wealth Advisors LLC Has $256,000 Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

EP Wealth Advisors LLC increased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 10.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,358 shares of the medical equipment provider’s stock after acquiring an additional 225 shares during the period. EP Wealth Advisors LLC’s holdings in Zimmer Biomet were worth $256,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. Chicago Partners Investment Group LLC boosted its position in shares of Zimmer Biomet by 3.3% during the 4th quarter. Chicago Partners Investment Group LLC now owns 2,894 shares of the medical equipment provider’s stock worth $349,000 after acquiring an additional 92 shares in the last quarter. North Star Investment Management Corp. boosted its position in Zimmer Biomet by 16.6% in the first quarter. North Star Investment Management Corp. now owns 669 shares of the medical equipment provider’s stock valued at $88,000 after buying an additional 95 shares in the last quarter. First Bancorp Inc ME raised its stake in shares of Zimmer Biomet by 5.3% during the first quarter. First Bancorp Inc ME now owns 1,970 shares of the medical equipment provider’s stock valued at $260,000 after acquiring an additional 100 shares during the last quarter. Ballentine Partners LLC raised its stake in shares of Zimmer Biomet by 2.6% during the first quarter. Ballentine Partners LLC now owns 3,957 shares of the medical equipment provider’s stock valued at $522,000 after acquiring an additional 100 shares during the last quarter. Finally, Romano Brothers AND Company raised its stake in shares of Zimmer Biomet by 1.1% during the first quarter. Romano Brothers AND Company now owns 9,514 shares of the medical equipment provider’s stock valued at $1,256,000 after acquiring an additional 100 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Trading Up 0.5 %

Shares of Zimmer Biomet stock opened at $104.68 on Friday. Zimmer Biomet Holdings, Inc. has a 1-year low of $102.00 and a 1-year high of $133.90. The stock has a market cap of $21.54 billion, a P/E ratio of 22.66, a P/E/G ratio of 1.94 and a beta of 1.02. The stock’s 50 day simple moving average is $109.19 and its 200-day simple moving average is $114.16. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 0.63.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.02. The company had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.94 billion. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. The firm’s quarterly revenue was up 3.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.82 earnings per share. Analysts predict that Zimmer Biomet Holdings, Inc. will post 8 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be issued a $0.24 dividend. The ex-dividend date is Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.92%. Zimmer Biomet’s payout ratio is 20.78%.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ZBH. Raymond James decreased their price target on shares of Zimmer Biomet from $138.00 to $128.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. Piper Sandler cut shares of Zimmer Biomet from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $140.00 to $115.00 in a report on Monday, July 1st. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Tuesday, September 17th. Oppenheimer reduced their price objective on shares of Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. Finally, Royal Bank of Canada reduced their price target on shares of Zimmer Biomet from $140.00 to $130.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $125.05.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.